• Home
  •  / Merrimack Pharmaceuticals

Merrimack Pharmaceuticals

OverviewSuggest Edit

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA and with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, the Company is building one of the most robust oncology pipelines in the industry.

TypePublic
Founded2000
HQCambridge, MA, USMap
Websitemerrimack.com
Employee Ratings3More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2019)27(-62%)
Revenue (FY, 2016)$144.3 M(+62%)
Share Price (Jan 2021)$7.6
Cybersecurity ratingCMore

Key People/Management at Merrimack Pharmaceuticals

Richard Peters

Richard Peters

President and Chief Executive Officer

Merrimack Pharmaceuticals Office Locations

Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, MA, US (HQ)
1 Kendall Square
Show all (1)

Merrimack Pharmaceuticals Financials and Metrics

Merrimack Pharmaceuticals Revenue

Merrimack Pharmaceuticals's revenue was reported to be $144.27 m in FY, 2016 which is a 61.6% increase from the previous period.
USD

Net income (Q3, 2020)

(1.0m)

EBIT (Q3, 2020)

(1.0m)

Market capitalization (20-Jan-2021)

101.6m

Closing stock price (20-Jan-2021)

7.6

Cash (30-Sept-2020)

15.8m
Merrimack Pharmaceuticals's current market capitalization is $101.6 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

48.9m47.8m102.8m89.3m144.3m

Revenue growth, %

115%(13%)62%

Cost of goods sold

46.0k6.9m

Gross profit

89.2m137.4m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

11.3m12.1m11.3m14.7m18.5m6.9m13.0m27.8m28.0m14.8m36.6m16.4m21.3m33.7m28.1m

Cost of goods sold

711.0k1.9m1.0m

Gross profit

20.6m31.8m27.1m

Gross profit Margin, %

97%94%96%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

37.7m65.1m35.7m185.6m21.5m93.4m20.1m16.6m

Accounts Receivable

9.3m5.9m3.3m6.5m17.5m100.0k

Prepaid Expenses

9.0m5.5m4.7m5.5m1.4m4.2m2.1m

Inventories

3.7m14.6m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

30.6m32.0m27.9m28.4m30.9m105.5m66.9m77.8m100.3m28.8m33.7m56.4m48.2m21.5m36.5m17.2m135.5m107.2m34.3m22.5m49.8m36.5m36.9m20.9m18.0m15.7m15.8m

Accounts Receivable

6.0m6.9m6.1m9.8m14.5m8.8m12.2m6.6m2.6m4.2m1.8m2.1m15.6m19.3m22.2m43.0k43.0k190.0k

Prepaid Expenses

6.5m6.6m11.3m10.2m9.2m8.9m2.5m4.4m5.8m3.2m5.4m6.4m4.5m4.6m4.1m2.3m5.9m8.0m844.0k1.7m1.8m4.6m2.1m1.5m1.9m3.6m2.9m

Inventories

8.1m12.3m14.8m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(91.3m)(130.7m)(83.6m)(147.8m)(153.5m)470.9m(40.5m)(17.3m)

Depreciation and Amortization

3.7m2.6m3.2m4.3m6.2m5.2m4.1m2.2m

Inventories

(3.7m)(9.7m)

Accounts Payable

7.0m13.3m(646.0k)13.6m(3.9m)(9.3m)(3.8m)(12.1m)
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(23.3m)(43.3m)(66.5m)(28.2m)(58.2m)(98.3m)(27.8m)(46.0m)(74.1m)(34.4m)(57.3m)(99.7m)(38.7m)(89.6m)(119.9m)(30.2m)480.7m483.8m(17.8m)(35.6m)(31.6m)(10.5m)(19.9m)(20.6m)249.0k(914.0k)(1.9m)

Depreciation and Amortization

1.4m2.2m3.0m700.0k1.3m1.9m886.0k2.2m2.8m1.1m2.1m4.3m1.5m3.0m5.2m1.2m2.1m2.8m1.2m2.3m3.2m1.2m2.2m2.2m

Inventories

(4.4m)(8.4m)(10.7m)

Accounts Payable

(2.1m)(1.9m)(3.9m)6.9m11.4m19.7m(4.5m)(6.0m)(2.1m)4.6m7.5m335.0k(1.2m)(7.1m)(2.4m)8.1m2.5m(3.1m)(2.4m)(2.0m)1.1m(4.5m)(9.9m)(10.1m)215.0k(435.0k)(496.0k)
show all
USDQ1, 2012

Financial Leverage

-0.2 x
Show all financial metrics

Merrimack Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

Learn more about our premium products
SecurityScorecard logo

Merrimack Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Merrimack Pharmaceuticals Online and Social Media Presence

Merrimack Pharmaceuticals's Trends

Embed Graph

Merrimack Pharmaceuticals News and Updates

September 19, 2019

Merrimack Pharmaceuticals Announces Changes to Board of Directors

Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective Immediately.read more
April 09, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
May 08, 2018

Merrimack Pharmaceuticals' (MACK) CEO Richard Peters on Q1 2018 Results - Earnings Call Transcript

April 19, 2018

Merrimack Pharmaceuticals Potential Catalyst A Likely Bust

Merrimack Pharmaceuticals Blogs

November 05, 2020

Merrimack Reports Third Quarter 2020 Financial Results

Merrimack Reports Third Quarter 2020 Financial Results Content Import Thu, 11/05/2020 - 08:20 Merrimack Reports Third Quarter 2020 Financial Results November 5, 2020 This release is a backfill from a News Wire Earnings CAMBRIDGE,…
August 07, 2020

Merrimack Reports Second Quarter 2020 Financial Results

Merrimack Reports Second Quarter 2020 Financial Results Content Import Fri, 08/07/2020 - 08:20 Merrimack Reports Second Quarter 2020 Financial Results August 7, 2020 This release is a backfill from a News Wire Earnings CAMBRIDGE,…
May 07, 2020

Merrimack Reports First Quarter 2020 Financial Results

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020 . “We are pleased to report that we have significantly reduced our operating
April 02, 2020

Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2020-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical
December 03, 2019

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan Content Import Tue, 12/03/2019 - 09:15 Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan December 3, 2019 This release is a backfill from a News Wire …
December 03, 2019

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend Content Import Tue, 12/03/2019 - 08:45 Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend December 3, 2019 This …
Show more

 Merrimack Pharmaceuticals Frequently Asked Questions

  • When was Merrimack Pharmaceuticals founded?

    Merrimack Pharmaceuticals was founded in 2000.

  • Who are Merrimack Pharmaceuticals key executives?

    Merrimack Pharmaceuticals's key executives are Richard Peters.

  • How many employees does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 27 employees.

  • Who are Merrimack Pharmaceuticals competitors?

    Competitors of Merrimack Pharmaceuticals include Enochian BioSciences, Mirati Therapeutics and Del Mar Pharmaceuticals.

  • Where is Merrimack Pharmaceuticals headquarters?

    Merrimack Pharmaceuticals headquarters is located at 1 Kendall Square, Cambridge.

  • Where are Merrimack Pharmaceuticals offices?

    Merrimack Pharmaceuticals has an office in Cambridge.

  • How many offices does Merrimack Pharmaceuticals have?

    Merrimack Pharmaceuticals has 1 office.